NCT04979325 is a clinical trial in Extracorporeal Membrane Oxygenation, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT04979325?

NCT04979325 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What condition does NCT04979325 study?

NCT04979325 studies Extracorporeal Membrane Oxygenation, Cardiopulmonary Resuscitation, Epidemiology.

Is NCT04979325 still recruiting?

NCT04979325 is currently status unknown. Last updated 28 July 2021.

Last reviewed 2021-07-28 · How we verify

NCT04979325

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cross-sectional Survey of Zhejiang ECMO Application

Status unknown Last updated 28 July 2021

What this trial tests

trial in Extracorporeal Membrane Oxygenation in 1 participant. Status unknown.

Timeline

1 August 2021

Primary endpoint
30 August 2021

1 September 2021

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	1
Start date	1 August 2021
Primary completion	30 August 2021
Estimated completion	1 September 2021
Sites	1 location across China

Conditions studied

Extracorporeal Membrane Oxygenation — all drugs for Extracorporeal Membrane Oxygenation →
Cardiopulmonary Resuscitation — all drugs for Cardiopulmonary Resuscitation →
Epidemiology — all drugs for Epidemiology →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

Eligibility, any sex, with Extracorporeal Membrane Oxygenation or Cardiopulmonary Resuscitation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Extracorporeal lung oxygenation (ECMO) was first used in neonates in the 1970s and is now widely used to treat adult patients with intractable shock and respiratory failure who have failed various types of conventional life support. According to the Extracorporeal Life Support Organization (ELSO), a total of 61,193 adult patients worldwide received ECMO in 2019. According to the Extracorporeal Life Support Organization (ELSO), a total of 61,193 adult patients were treated with ECMO worldwide in 2019, including 25,631 VV-ECOM, 12,836 VA, and 5086 ECPR. The number of ECMO cases and hospitals in Zhejiang province are increasing year by year, and they play an irreplaceable role in various critical care resuscitation, especially in response to public emergencies, but there is a lack of precise data on the current status of ECMO implementation. This study aims to investigate the implementation of ECMO, problems and needs of hospitals at all levels in Zhejiang Province, and provide reference for further improving the capacity and quality of ECMO application in the province.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Extracorporeal Membrane Oxygenation

Currently open trials in the same condition.

NCT06862700 — Effect of Reduced Vasopressors on Mortality in ECMO-supported Cardiogenic Shock Patients · recruiting
NCT06560164 — Restrictive Versus Liberal Thresholds for RBC Transfusion in ECMO · NA · recruiting
NCT06369584 — Prone Position During ECMO in Pediatric Patients With Severe ARDS · NA · recruiting
NCT05574296 — Hydrogen's Feasibility and Safety as a Therapy in ECPR · Phase 1 · recruiting
NCT06660784 — Mechanism of Nitric Oxide on Ventilator-induced Diaphragm Dysfunction with Extracorporeal Membrane Lung Assistance · active not recruiting

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04979325 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 28 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04979325.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing